Barbara W. Bodem

October 4, 2026

BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.

October 11, 2026

McKesson moves to acquire Option Care Health in $5.8B deal. Option Care Health is the target of a $5.8 billion acquisition by McKesson, which has lifted the stock in recent trading. The deal is under legal review, and several analysts have lowered their ratings, with UBS moving to neutral and William Blair to market‑perform. The mixed reactions reflect both the premium offered and the uncertainties around regulatory approval.

October 17, 2026

Enovis Gathers Fresh Attention After Reaffirming 2026 Guidance. Enovis has attracted new interest as analysts discuss its 2026 outlook. A recent review lowered the price target to $34 while maintaining a positive stance. The stock is trading near the top of its 52‑week range, and recent signals show a breakout and positive RSI divergence. These developments may influence how investors view the company’s valuation.